FY2024 EPS Estimates for Danaher Cut by Zacks Research

Danaher Co. (NYSE:DHR) – Investment analysts at Zacks Research lowered their FY2024 earnings estimates for Danaher in a research note issued on Tuesday, November 12th. Zacks Research analyst R. Department now anticipates that the conglomerate will post earnings of $7.49 per share for the year, down from their previous estimate of $7.56. The consensus estimate for Danaher’s current full-year earnings is $7.51 per share. Zacks Research also issued estimates for Danaher’s Q4 2024 earnings at $2.14 EPS, Q1 2025 earnings at $2.05 EPS, Q2 2025 earnings at $1.91 EPS, Q3 2025 earnings at $1.94 EPS, Q4 2025 earnings at $2.34 EPS, FY2025 earnings at $8.24 EPS, Q1 2026 earnings at $2.21 EPS, Q2 2026 earnings at $2.25 EPS and FY2026 earnings at $9.28 EPS.

A number of other equities analysts have also recently issued reports on the company. The Goldman Sachs Group upped their price objective on Danaher from $225.00 to $250.00 and gave the stock a “neutral” rating in a report on Wednesday, July 24th. Wells Fargo & Company assumed coverage on shares of Danaher in a research note on Tuesday, August 27th. They issued an “equal weight” rating and a $280.00 price objective for the company. Royal Bank of Canada cut their price target on shares of Danaher from $333.00 to $311.00 and set an “outperform” rating for the company in a research report on Wednesday, October 23rd. Robert W. Baird dropped their target price on Danaher from $278.00 to $277.00 and set an “outperform” rating for the company in a report on Wednesday, October 23rd. Finally, StockNews.com upgraded shares of Danaher from a “hold” rating to a “buy” rating in a report on Wednesday, November 6th. Five investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $287.16.

Danaher Trading Up 0.8 %

Shares of DHR opened at $241.47 on Thursday. The firm’s 50 day simple moving average is $263.88 and its 200 day simple moving average is $260.77. The company has a market capitalization of $174.41 billion, a P/E ratio of 46.08, a P/E/G ratio of 4.40 and a beta of 0.85. Danaher has a 1-year low of $200.36 and a 1-year high of $281.70. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.57 by $0.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The company had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.59 billion. During the same quarter last year, the company earned $2.02 earnings per share. The firm’s quarterly revenue was up 3.1% on a year-over-year basis.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, October 25th. Shareholders of record on Friday, September 27th were paid a $0.27 dividend. This represents a $1.08 annualized dividend and a yield of 0.45%. The ex-dividend date was Friday, September 27th. Danaher’s payout ratio is currently 20.61%.

Insider Buying and Selling at Danaher

In related news, SVP Georgeann Couchara sold 952 shares of the business’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the sale, the senior vice president now owns 4,212 shares in the company, valued at approximately $1,130,374.44. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 11.10% of the company’s stock.

Institutional Trading of Danaher

A number of large investors have recently made changes to their positions in the stock. Benjamin Edwards Inc. raised its position in Danaher by 1.8% during the 2nd quarter. Benjamin Edwards Inc. now owns 2,153 shares of the conglomerate’s stock worth $538,000 after buying an additional 38 shares during the last quarter. Wedge Capital Management L L P NC boosted its stake in shares of Danaher by 3.2% in the third quarter. Wedge Capital Management L L P NC now owns 1,231 shares of the conglomerate’s stock valued at $342,000 after buying an additional 38 shares in the last quarter. Patrick M Sweeney & Associates Inc. raised its position in Danaher by 3.4% in the second quarter. Patrick M Sweeney & Associates Inc. now owns 1,230 shares of the conglomerate’s stock worth $307,000 after acquiring an additional 40 shares in the last quarter. Trust Co of Kansas increased its holdings in shares of Danaher by 4.1% in the 2nd quarter. Trust Co of Kansas now owns 1,022 shares of the conglomerate’s stock valued at $255,000 after purchasing an additional 40 shares in the last quarter. Finally, Abacus Planning Group Inc. grew its holdings in shares of Danaher by 0.7% in the 2nd quarter. Abacus Planning Group Inc. now owns 5,439 shares of the conglomerate’s stock worth $1,359,000 after acquiring an additional 40 shares during the period. 79.05% of the stock is owned by hedge funds and other institutional investors.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.